Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqGS - Nasdaq Real Time Price USD

AstraZeneca PLC (AZN)

Compare

73.79

+0.95

+(1.30%)

At close: March 28 at 4:00:00 PM EDT

73.75

-0.04

(-0.06%)

After hours: March 28 at 7:50:49 PM EDT

Is AstraZeneca (AZN) the Best ADR Stock to Buy According to Hedge Funds?

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other best ADR stocks. American Depositary Receipts (ADR) are US-listed securities that represent shares in foreign companies, allowing American investors […]

Insider Monkey 2 days ago

AZN
+1.30%
Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet

The average brokerage recommendation (ABR) for Astrazeneca (AZN) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks 3 days ago

AZN
+1.30%
How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.

Pharma Voice 3 days ago

AMGN
+0.39%
AZN
+1.30%
AstraZeneca says new results reinforce Tagrisso as backbone therapy

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s (AZN) TAGRISSO, as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated non-small cell lung cancer. Highlights include: LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy; SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with h

TipRanks 4 days ago

AZN
+1.30%
AZNCF
Astrazeneca (AZN) Stock Moves -0.45%: What You Should Know

In the most recent trading session, Astrazeneca (AZN) closed at $72.72, indicating a -0.45% shift from the previous trading day.

Zacks 4 days ago

AZN
+1.30%
^GSPC
New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

WILMINGTON, Del., March 25, 2025--New study results presented at the European Lung Cancer Congress (ELCC) 2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO® (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Highlights include:

Business Wire 5 days ago

AZN
+1.30%
AZNCF
Assemblin to upgrade AstraZeneca’s Gärtuna plant in Sweden

The upgrade focuses on enhancing the cooling capacity at the plant and supplying supplementary equipment installation.

World Construction Network 6 days ago

AZN
+1.30%
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Zacks 6 days ago

AZN
+1.30%
AstraZeneca to invest $2.5bn in R&D centre in China

The new centre will focus on early-stage research and clinical development, supported by data science and AI labs.

Pharmaceutical Technology 6 days ago

AZN
+1.30%
Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead

AstraZeneca (NASDAQ: AZN), a U.K.-based pharmaceutical giant, is one of them; its stock is up by an impressive 16% since January. AstraZeneca's shares fell off a cliff late last year when it announced the arrest of some of its executives in China, including Leon Wang, the drugmaker's president in the country. Last year, its revenue jumped by 18% year over year to $54.1 billion, an excellent performance for a pharmaceutical giant.

Motley Fool 7 days ago

AZN
+1.30%
Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks fell late Friday afternoon, with the NYSE Health Care Index down 0.6% and the Hea

PREMIUM
MT Newswires 9 days ago

AZN
+1.30%
ALNY
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

Pfizer sells 7.3% remaining stake in Haleon. FDA approves the expanded use of JNJ and NVS drugs.

Zacks 9 days ago

AZN
+1.30%
HLN

PFE
Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 9 days ago

KRYS

AZN
+1.30%
AstraZeneca to invest £2bn in Beijing amid China investigation

AstraZeneca has unveiled plans to invest £2bn in Beijing months after Chinese authorities detained the company’s local boss over alleged illegal activity.

The Telegraph 9 days ago

AZN
+1.30%
Micron, Johnson & Johnson, AstraZeneca: Top Stocks

Morning Brief host Brad Smith tracks several of this morning's trending stocks and market stories, including Micron Technology's (MU) guidance overshadowing its fiscal second quarter results, Johnson & Johnson's (JNJ) plans to invest in US manufacturing, and AstraZeneca's (AZN) own investment into a Beijing facility. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 9 days ago

MU

AZN
+1.30%
AZNCF
AstraZeneca to Invest $2.5 Billion in China Amid Probes

The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies, at a time when Chinese authorities are probing it.

The Wall Street Journal 9 days ago

AZN
+1.30%
AZNCF
AstraZeneca deepens China investment; Editas loses CFO to Dyne

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

BioPharma Dive 9 days ago

AZN
+1.30%
EDIT

PFE
AstraZeneca Invests $2.5 Billion in Beijing Hub Amid Probe

(Bloomberg) -- AstraZeneca Plc will invest $2.5 billion in a new research center in Beijing, in a major show of commitment to China just months after the company’s top executive there was detained by authorities. Most Read from BloombergNew York Subway Ditches MetroCard After 32 Years for Tap-And-GoLA Faces $1 Billion Budget Hole, Warns of Thousands of LayoffsDespite Cost-Cutting Moves, Trump Plans to Remake DC in His StyleAmtrak CEO Departs Amid Threats of a Transit Funding PullbackChicago Tran

Bloomberg 9 days ago

AZN
+1.30%
AstraZeneca to invest $2.5bn in China after scandal

AstraZeneca is investing $2.5bn in research and development and manufacturing in Beijing, as the drugmaker tries to move on after a scandal that...

PREMIUM
Financial Times 9 days ago

AZN
+1.30%
AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year. Chief Executive Pascal Soriot was in Beijing and met with the city's mayor to reveal the investment, along with two licensing deals with Chinese companies, and a joint venture with a third Chinese firm on vaccines, saying they all showed the company's commitment to the world's No. 2 economy. "This $2.5 billion investment reflects our belief in the world-class life sciences ecosystem in Beijing, the extensive opportunities that exist for collaboration and access to talent, and our continued commitment to China," Soriot said in a statement.

Reuters 9 days ago

AZN
+1.30%

Performance Overview

Return	AZN	FTSE 100 (^FTSE)
YTD	+14.14%	+5.94%
1-Year	+10.32%	+8.88%
3-Year	+20.73%	+15.87%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (AZN)

Is AstraZeneca (AZN) the Best ADR Stock to Buy According to Hedge Funds?

Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet

How AZ and Amgen’s Tezspire respiratory data ups the ‘level of ambition’ in immunology

AstraZeneca says new results reinforce Tagrisso as backbone therapy

Astrazeneca (AZN) Stock Moves -0.45%: What You Should Know

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

Assemblin to upgrade AstraZeneca’s Gärtuna plant in Sweden

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

AstraZeneca to invest $2.5bn in R&D centre in China

Forget the Correction: This Stock Is Defying the Sell-Off, and There Might Be More Upside Ahead

Sector Update: Health Care Stocks Retreat Late Afternoon

Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals

Krystal Biotech (KRYS) Up 3.3% Since Last Earnings Report: Can It Continue?

AstraZeneca to invest £2bn in Beijing amid China investigation

Micron, Johnson & Johnson, AstraZeneca: Top Stocks

AstraZeneca to Invest $2.5 Billion in China Amid Probes

AstraZeneca deepens China investment; Editas loses CFO to Dyne

AstraZeneca Invests $2.5 Billion in Beijing Hub Amid Probe

AstraZeneca to invest $2.5bn in China after scandal

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals

Performance Overview